Kate Rochlin, PhD, serves as President and Chief Operating Officer, bringing more than 15 years of leadership experience across early-stage biotechnology, company building, and strategic operations. Since joining the company in 2020, she has played a central role in shaping corporate strategy, strengthening operational execution, advancing intellectual property strategy, and building high-performing cross-functional teams. She was appointed Chief Operating Officer in December 2021 and elevated to President in recognition of her broad leadership impact.
Prior to joining, Dr. Rochlin held senior leadership roles at Curadigm, a Cambridge, MA–based biotechnology company spun out of Nanobiotix, where she most recently served as Chief Business Officer. There, she helped lead the company’s spin-out and built strategic collaborations around a novel platform designed to enhance therapeutic bioavailability. Dr. Rochlin has been recognized for her leadership and impact in biotechnology, including being named one of Crain’s New York Business’ Top Women in Tech.